Biological agents are used to treat a variety of diseases in many therapeutic areas, including oncology, hematology, rheumatology, gastroenterology, dermatology, neurology, respiratory diseases, hormone deficiency and infections. Since biologics constitute many of the recently approved new therapies, clinical research of drug-drug interactions with biologics has been discussed. Here, we present a personal view of drug-drug interactions with monoclonal antibodies, a predominant class of therapeutic biologics. In this line, we think that the interactions of biological agents with other chemical drugs represent an important issue, completely unknown and with potentially prominent clinical implications, that will have to be taken into account in coming years.
Health care practitioners around the world are facing an unprecedented challenge to improve care quality, prevent medical errors and maintain efficiency while simultaneously reducing costs of health systems. Identifying potentially harmful prescription drug interactions (before they have a chance to manifest themselves in the clinic) helps accomplish this goal in many ways. Unexpected clinical drug interactions can lead to a higher risk of adverse events and substantially reduce the probability of treatment success. Either of these outcomes can significantly increase resource utilization and unnecessarily prolong patient suffering and illness. It is because of that, a complete assessment of a new drug's potential for clinical drug interactions, including a thorough evaluation of any underlying pharmacokinetic or pharmacodynamic mechanisms, is always necessary 1 .
Nowadays, biological therapies play a crucial role in the pharmacotherapy of a variety of therapeutic disease areas, including those in hematology, oncology, rheumatology, gastroenterology, dermatology, neurology, hormone deficiency and infections 2 . Thus, clinicians are facing a new era of therapeutic treatment with profound differences in their chemical, pharmacokinetic and pharmacodynamic characteristics in comparison with the conventional therapies with small molecule drugs 3 . Chemically, therapeutic biologics are different than small chemical agents 4 since they are mainly represented by (glyco) proteins composed of L-amino acids and various sugar molecules (Table 1) .
There are several categories of therapeutic biologics, including monoclonal antibodies (mAbs), recombinant protein therapeutics (e.g. therapeutic cytokines), hybrid and modified molecules (e.g. pegylated, glycoengineered, and fusion proteins), endogenous proteins/peptides (e.g. insulin) and others (e.g. gene transfer products and antisense oligonucleotides). Of all these categories, mAbs represent a predominant class of therapeutic protein biologics 5 . More than 150 mAbs are in different stages of clinical development and, to date, 44 therapeutic mAbs have been approved for use by the FDA and EMA 6 . Although only a few formal drug-drug interaction studies have been performed with therapeutic mAbs, there are several recent studies giving excellent overviews of drug-drug interactions for therapeutic biologics including therapeutic mAbs 7, 8 . In general, overall results of the literature review suggest that potential interaction effects between a therapeutic mAb and a coadministered small-molecule drug should be more thoroughly studied 6 .
A formal assessment of the drug-drug interaction potential of any investigational drug product requires multiple metabolic and pharmacokinetic evaluations. As for small-molecule drugs, investigating the drugdrug interaction potential is relatively easy. For mAbs, it is more complicated due to their complex nature. High molecular weight mAbs are often genetically engineered to demonstrate strong specificity for a particular human antigen target. Consequently, mAbs usually have few clinically relevant animal models (other than nonhuman primates) in which to conduct appropriate nonclinical studies. Similarly, clinical drug-drug interaction studies of mAbs with long elimination half-lives raise definite operational challenges since conventional crossover studies with adequate washout periods are difficult to conduct (Table 2 ). Added to all of this is the fact that the current regulatory guidance on the design and conduct of in vitro and in vivo drug-drug interaction studies applies more readily to small-molecule drugs 9 .
Very often, a drug-drug interaction results in a significant variation of the pharmacokinetic profiles caused by the common metabolic pathways involved in the disposition of the co-administered drugs. In particular, the inhibition or the induction of a particular isoform of cytochrome P450 (CYP450) or specific drug transporters by a single drug can dramatically affect the pharmacokinetics of a second drug when co-administered. Since the metabolism, distribution and elimination of mAbs are not mediated by CYP450 or drug transporters, mAbs are not expected to compete directly with chemically derived drugs. Thus, from a mechanistic perspective, the likelihood of direct drugmAbs interaction occurring during their co-administration is unlikely to be high 10 .
It has been suggested that some interactions between a mAb and a coadministered small-molecule drug could be attributed to a subsequent modulation of the activity between the mAbs and the Fcγ receptors on effector cells (i.e., lymphocytes, monocytes, macrophages and neutrophils) or to the concomitant effects of the small-molecule drug on the level of Fcγ receptor expression 11 . Other studies have asserted that certain mAbs may significantly affect Inflammation-evoked changes in drug transport proteins as a result of treatment with a mAb could also potentially affect the disposition of certain small-molecule drugs 10 .
Finally, in some cases where a concomitantly administered drug is processed by both CYP enzymes and transport proteins, the pharmacokinetic behavior may be greatly affected if immune-mediated changes related to mAb therapy were to occur simultaneously in the involved CYP enzymes and drug transport proteins. Recently, several combinations of mAbs have been studied in various stages of clinical development. A possible mechanism of interaction with these combinations would involve the FcRn-mediated recycling 6 . However, given the total amount of endogenous IgG of 50-100 g, the usual dose of most mAbs <10 mg/kg is not predicted to affect the total IgG plasma concentration 13 .
As mentioned above, the pharmacokinetics of mAbs is complex and differs from that of small molecule drugs. Their parenteral administration, the different pathways involved in their clearance and their long elimination halflife are the most pronounced pharmacokinetic distinctions ( Table 2 ). The long half-life is partly the resultant of an important protective FcRn-based mechanism against degradation in the cell 14 . Monoclonal antibodies targeting a soluble antigen generally exhibit linear elimination whereas those targeting a membrane-bound antigen may exhibit non-linear elimination. The nonlinear clearance is due to the saturation of the target-mediated elimination of the mAbs. In addition, the immunogenicity of the mAbs is directly implicated in the clearance of mAbs, and their glycosylation pattern can influence this parameter 15 . Thus, and in contrast with the small molecule drugs, the mechanisms of pharmacokinetic interactions of mAbs are complex and currently are not well understood 16 . Theoretically, because of their different disposal mechanism, the pharmacokinetic interaction between mAbs and small molecule drugs is expected to be minimal, as well as for the mAbs combination since their catabolic pathways are essentially not saturable. So far, the interactions of mAbs with each other and with small molecule drugs have not shown significant changes in systemic exposure [17] [18] [19] [20] . Nevertheless, potentially clinically relevant interactions between mAbs and immunosuppressing drugs, such as methotrexate with infliximab, adalimumab and golimumab have already been documented 21 .
Small molecule drugs may affect the expression of the mAbs's target by altering their target-mediated clearance. Such case has been observed with statins and fibrates that induce the PCSK9 expression and thus the clearance of alirocumab and evolocumab, although this interaction is not considered clinically relevant 22, 23 . Similarly, chemotherapeutic agents may reduce the tumor burden and hence the target-mediated clearance as discussed with trastuzumab, whose clearance increases with tumor size and therefore Her2 expression. In this light, the target-mediated clearance of mAbs seems to be the area that requires more investigation, and it is likely to have additional evidences in the near future.
In summary, the pharmacological interactions of biological agents are not well known. Because biological agents are not metabolized by cytochrome P450 enzymes and do not interact with cell membrane transporters, it is generally perceived that they are free from interactions with small molecule drugs. However, the clearance of biological agents varies depending on the modulation of the immune response or by either increasing or reducing the expression of target cells of the biological agents, which can occur by the action of multiple synthetic chemical agents. Furthermore, some biological agents may modify the metabolism of chemical drugs through their effects on the expression of P450 system enzymes.
In this clinical perspective, we provide an outline of the pharmacokinetics properties and pharmacologic interactions of biological drugs, focusing on mAbs, and how these can interact with chemical synthesis molecules. Thus, we believe knowledge of them is important for clinicians and affects multiple clinical specialties. However, the current information about relevant drug-mAbs interactions are not well described and more formal studies are needed in this field. Personally, we think that the interactions of biological agents with other chemical drugs represent an important issue, completely unknown and with potentially prominent clinical implications, that will have to be taken into account in the daily clinical management in coming years.
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